Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Instil Bio Inc TIL

Healthcare Biotechnology
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a... see more

Recent & Breaking News (NDAQ:TIL)

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 21, 2024

Instil Bio Announces Strategic Update

GlobeNewswire January 16, 2024

Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

GlobeNewswire December 5, 2023

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2023

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

GlobeNewswire November 6, 2023

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2023

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

GlobeNewswire June 26, 2023

Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 11, 2023

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 31, 2023

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site

GlobeNewswire January 31, 2023

Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

GlobeNewswire January 9, 2023

Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)

Business Wire December 12, 2022

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

GlobeNewswire December 8, 2022

Instil Bio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Newsfile November 21, 2022

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 14, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

PR Newswire November 14, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

Newsfile November 9, 2022

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Newsfile November 8, 2022

Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 8, 2022

Instil Bio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Newsfile November 7, 2022